Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 6/20 | 0.47 |
| ▸ | FNTB | P49356 | 6/20 | 0.47 |
| ▸ | PGGT1B | P53609 | 6/20 | 0.47 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13563966 | 0.88 | CYP11B1 (0.42) | FNTAFNTBPGGT1BCYP11B1CYP11B2 | |
| SCHEMBL3628808 | 0.82 | CYP11B1 (0.60) | FNTAFNTBPGGT1BCYP11B1CYP11B2 | |
| SCHEMBL1097299 | 0.78 | CYP19A1 (0.42) | FNTAFNTBPGGT1BCYP11B1CYP11B2 | |
| SCHEMBL1040117 | 0.77 | CYP11B1 (0.50) | FNTAFNTBPGGT1BCYP11B1CYP11B2 | |
| SCHEMBL17894305 | 0.77 | FNTA (0.42) | FNTAFNTBPGGT1BCYP11B1CYP11B2 | |
| SCHEMBL14562263 | 0.77 | FNTA (0.44) | FNTAFNTBPGGT1BCYP11B1CYP11B2 | |
| SCHEMBL13563963 | 0.75 | CYP11B1 (0.43) | FNTAFNTBPGGT1BCYP11B1CYP11B2 | |
| SCHEMBL14562317 | 0.75 | CYP11B1 (0.43) | FNTAFNTBPGGT1BCYP11B1CYP11B2 | |
| SCHEMBL13563965 | 0.75 | CYP11B1 (0.45) | FNTAFNTBPGGT1BCYP11B1CYP11B2 | |
| SCHEMBL3465788 | 0.74 | CYP11B2 (0.41) | FNTAFNTBPGGT1BCYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100240641-A1 | Aldosterone Synthase and/or 11B-hydroxylase Inhibitors | PAPILLON JULIEN | 2010-09-23 | — | — | US | disclosed |
| US-20100240641-A1 | Aldosterone Synthase and/or 11B-hydroxylase Inhibitors | PAPILLON JULIEN | 2010-09-23 | — | — | US | disclosed |
| EP-2029604-A2 | ALDOSTERONE SYNTHASE AND/OR 11BETA-HYDROXYLASE INHIBITORS | Novartis AG (CH) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007139992-A2 | ALDOSTERONE SYNTHASE AND/OR 11β-HYDROXYLASE INHIBITORS | NOVARTIS AG (CH) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240641-A1 | Aldosterone Synthase and/or 11B-hydroxylase Inhibitors | HSD11B1, HSD11B2, CYP11B1 | FNTA 352/4885FNTB 245/4885PGGT1B 203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.